Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 3;2(1):vdaa076.
doi: 10.1093/noajnl/vdaa076. eCollection 2020 Jan-Dec.

Cervicomedullary hemangioblastoma treated with bevacizumab

Gloria Mak  1 , Almunder Algird  2 , Jeffrey Greenspoon  3 , John Provias  4 , Hal Hirte  3
Affiliations

Cervicomedullary hemangioblastoma treated with bevacizumab

Gloria Mak et al. Neurooncol Adv. .
No abstract available

Keywords: bevacizumab; hemangioblastoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
At the initial presentation, MRI revealed a mass at the cervicomedullary junction measuring 2 × 2.5 × 2.3 cm (A and B). After subtotal surgical resection (C and D), the size of the hemangioblastoma decreased to 1.6 × 0.6 × 1.1 cm. With 10 months of surveillance, the hemangioblastoma increased to 1.6 × 1.0 × 1.4 cm (E and F). There was an enlargement of the hemangioblastoma 1-month (mo) post-stereotactic radiosurgery, measuring 1.9 × 1.5 × 1.8 cm, with associated edema and hydrocephalus (G and H). Ongoing surveillance revealed a further increase of the hemangioblastoma (2.0 × 1.8 × 2.0 cm) and increased surrounding edema (I and J). After bevacizumab therapy, there was a decrease in the size of the hemangioblastoma, measuring 1.4 × 1.5 × 1.7 cm (K and L) and reduction of surrounding edema. Over 1 year of clinical surveillance, the hemangioblastoma has remained stable in size, measuring 1.4 × 1.6 × 1.7 cm (M and N).
Figure 2.
Figure 2.
Surgical resection from the cervicomedullary mass shows typical features of hemangioblastoma with numerous irregular small capillary-type vascular channels and an intervening cell population (so-called “stromal” cells) on hematoxylin and eosin (H&E) staining, 200× magnification (A) with the scale bar measuring 50 µm. There are prominent capillary-type vascular spaces highlighted by CD34-positive immunohistochemistry staining for endothelial cells, 200× magnification (B) with the scale bar measuring 50 µm. The non-vascular tumor cells (“stromal” cells) exhibit characteristic inhibin A positivity by immunohistochemistry, 200× magnification (C) with the scale bar measuring 50 µm. There is a very low proliferative activity of the tumor with only a rare tumor cell nucleus positive for Ki67 on immunohistochemistry, 200× magnification (D) with the scale bar measuring 50 µm.
See this image and copyright information in PMC

References

    1. Gläsker S, Klingler JH, Müller K, et al. . Essentials and pitfalls in the treatment of CNS hemangioblastomas and von Hippel-Lindau disease. Cent Eur Neurosurg. 2010;71(2):80–87. - PubMed
    1. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617–623. - PMC - PubMed
    1. Pierscianek DWS, Keyvani K, El Hindy N, et al. . Study of angiogenic signaling pathways in hemangioblastoma. Neuropathology. 2017;37(1):3–11. - PubMed
    1. Wind JJ, Bakhtian KD, Sweet JA, et al. . Long-term outcome after resection of brainstem hemangioblastomas in von Hippel-Lindau disease. J Neurosurg. 2011;114(5):1312–1318. - PMC - PubMed
    1. Kano H, Shuto T, Iwai Y, et al. . Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study. J Neurosurg. 2015;122(6):1469–1478. - PubMed

LinkOut - more resources